RESEARCH TRIANGLE PARK, NC--(Marketwire - November 22, 2010) - The population of Brazil, Russia, India and China, roughly three billion people, coupled with these countries' growing emphasis on strong physician-patient relationships, makes Emerging Markets a hotbed of clinical research activity, according to a new study.
Emerging Markets Clinical Development Series: Brazil, Russia, India and China (BRIC) provides in-depth analysis on each of these countries' benefits, advantages and challenges. The study is the latest in a series of studies from Cutting Edge Information about managing clinical trials in Emerging Markets. According to the research, patient availability is one of the top reasons driving drug companies to look to Emerging Markets for clinical trial management.
"Overall, the benefits outweigh the challenges of entering these markets," said Jason Richardson, president of Cutting Edge Information. "Patients' respect for their physicians' recommendations in these markets provides clinical teams with a better chance to finish clinical testing with complete data and on time."
A scientific advantage of the new clinical model is that much of the patient population is treatment naive, meaning that they have not already used other treatments that could change clinical results. These treatment-naive patients provide clearer effectiveness results when testing new medications.
Emerging Markets Clinical Development Series: BRIC (http://www.cuttingedgeinfo.com/bric-clinical-trials/) provides quantitative analysis of patient availability and retention within the BRIC countries.
"For example, clinical development executives ranked India as the emerging market with the greatest patient availability, followed closely by China," said Shaylyn Pike, senior research analyst at Cutting Edge Information. "With regard to patient retention, China, with the largest population of any country, took the top spot, followed by India."
The new research study analyzes the potential of the BRIC markets to fulfill clinical protocols and ultimately realize significant cost and time savings. It is designed to provide clinical development teams with best practices, strategies and metrics to develop the strongest possible Emerging Markets strategies:
- Eliminate stakeholder confusion about BRIC strategy
- Master trial management in Emerging Markets
- Clarify advantages and disadvantages to boost success rates
Contact Information:
For more information, contact
Eric Bolesh
+1 919-403-6583
For media inquiries, please contact
Stephanie Swanson
+1 919-403-6583